IgA Nephropathy
Conditions
Interventions
experimental group:Sirolimus: initial dose 1mg/d, target trough concentration 5-8µg/L,and supportive treatment
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: When patients meet conditions A-C, they enter a screening period during which they follow the usual treatment with an intensive support approach. If conditions A-E are met, you can be added to the group: A) Age: 18-69 years old; B) Primary IgA nephropathy confirmed by renal perforation pathology within the past year; C) Patients or family members can understand the study protocol and are willing to participate in the study, providing written informed consent; D) eGFR=30ml/min/1.73m2 (calculated using the ckd-epi formula) after at least 4 weeks of intensive supportive therapy; E) 24-hour urinary total protein 0.75 -- 3.0g after at least 4 weeks of intensive supportive therapy.
Exclusion criteria
Exclusion criteria: We exclude patients who have any of the following conditions:: A)Secondary IgA nephropathy, such as systemic lupus erythematosus, cirrhosis, IgA vasculitis, or other chronic kidney disease; B) Use of immunosuppressive therapy, including hormones or immunosuppressive agents, in the past 1 year; C) Other indications of the use of hormones or immunosuppressants, including IgA nephropathy with minimal lesions and the presence of crescents in > 50% of glomeruli in renal perforation pathology D) Combined with other circumstances affecting the use of rapamycin: (1) Active or occult infection, including HBV, CMV infection or latent or active tuberculosis; (2) have been diagnosed with malignant tumors within the last 5 years; (3) Current pregnancy or lactation (4) A woman of reproductive age has a family planning while taking medication E) Unqualified hypertension control (systolic blood pressure > 160mmHg or diastolic blood pressure > 110mmHg) F) The clinician judged that the patient was unable to comply with the study protocol G) Participate in other clinical trials at the same time H) Withdrawal criteria: After enrollment, patients requested to withdraw from the study due to various considerations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Creatinine;24 hour urine protein;Serum albumin;blood lipid; | — |
Countries
China
Contacts
Public ContactXuemei Li
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed